Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/01/2012US20120052292 Novel medical device coatings
03/01/2012US20120052142 BIOLOGICALLY ACTIVE COMPOSITIONS FROM Schisandra chinensis FOR TREATING COLORECTAL CANCER
03/01/2012US20120052141 Novel use of compounds for treating and alleviating cellulite
03/01/2012US20120052130 Gpr 119 modulators
03/01/2012US20120052128 Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
03/01/2012US20120052126 Nanoemulsions Containing Antioxidants And Other Health-Promoting Compounds
03/01/2012US20120052125 Cholesteryl Sulfate-Containing Composition As A Haemostatic
03/01/2012US20120052124 Silk fibroin systems for antibiotic delivery
03/01/2012US20120052122 Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor
03/01/2012US20120052121 New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
03/01/2012US20120052120 Nanotechnology formulation of poorly soluble compounds
03/01/2012US20120052119 Nanoencapsulated delta-9-tetrahydrocannabinol
03/01/2012US20120052118 Apparatus and process for encapsulating capsules or other solid dosage forms within capsules
03/01/2012US20120052117 Soft capsule of butylphthalide and a process for preparing the same
03/01/2012US20120052115 Nanocarrier therapy for treating invasive tumors
03/01/2012US20120052114 Apparatus and methods for making nanosomes loaded with nucleic acid
03/01/2012US20120052113 Transdermal preparation
03/01/2012US20120052111 Adhesive Laminates for Rapid Wound Occlusion
03/01/2012US20120052110 Methods and compositions for promoting wound healing
03/01/2012US20120052108 Macrocyclic lactone drug delivery system
03/01/2012US20120052099 Pharmaceutical composition containing arbidol in the form of phospholipid nanoparticles
03/01/2012US20120052098 Liquid ganaxolone formulations and methods for the making and use thereof
03/01/2012US20120052096 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
03/01/2012US20120052095 Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
03/01/2012US20120052093 Compositions and methods for preventing and treating uterine disease
03/01/2012US20120052079 Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
03/01/2012US20120052071 Tumor markers and methods of use thereof
03/01/2012US20120052062 Methods for Treatment of Non-Small Cell Lung Cancer
03/01/2012US20120052061 Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
03/01/2012US20120052058 Methods of managing the blood coagulation and pharmaceutical compositions related thereto
03/01/2012US20120052057 method for selecting responders to blockade of integrin receptors
03/01/2012US20120052055 Method of treating thrombocytopenia
03/01/2012US20120052053 Compositions and methods for the treatment of altered alpha-synuclein function
03/01/2012US20120052051 Method of treating diabetes - related vascular complications
03/01/2012US20120052046 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections
03/01/2012US20120052044 Uses of mammalian cytokine; related reagents
03/01/2012US20120052043 Chemokine-Chaperone Fusion Proteins
03/01/2012US20120052042 Amphiphilic compounds and self-assembling compositions made therefrom
03/01/2012US20120052040 Polymer compositions and methods for their use
03/01/2012US20120052028 Cinnamic acid ascorbates
03/01/2012US20120052026 Oral compositions containing biphenol antibacterial compounds
03/01/2012US20120052025 Borinic compositions
03/01/2012US20120052021 Inhibition of undesired sensory effects by the compound camphor
03/01/2012US20120052019 Certain chemical entities, compositions, and methods
03/01/2012US20120052012 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions
03/01/2012US20120052006 Gold/lanthanide nanoparticle conjugates and uses thereof
03/01/2012US20120052005 Combination therapy to improve drug efficiency
03/01/2012DE102010036213A1 Use of peracylated hexoses or peracylated pentoses for improving or normalizing the energy and constructive metabolism of body cells, preferably cells of the central nervous system, muscles and liver
03/01/2012DE102010035744A1 Imidazolonylchinoline Imidazolonylchinoline
03/01/2012DE102010005124A1 Feste pharmazeutische Zusammensetzung umfassend Lercanidipin A solid pharmaceutical composition comprising lercanidipine
03/01/2012CA2811990A1 Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
03/01/2012CA2809830A1 Compounds that modulate intracellular calcium
03/01/2012CA2809767A1 Theobromine in combination with an expectorant or a mucolytic for use in therapy
03/01/2012CA2809633A1 Receptor-type kinase modulator and methods of treating polycystic kidney disease
03/01/2012CA2809388A1 Crystal of a free tricyclic pyrazolopyrimidine derivative
03/01/2012CA2809341A1 Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012CA2809333A1 Furopyridine derivatives
03/01/2012CA2809331A1 Triazolopyrazine derivatives
03/01/2012CA2809287A1 Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012CA2809263A1 Pharmaceutical composition and administrations thereof
03/01/2012CA2809261A1 Potent and selective inhibitors of hepatitis c virus
03/01/2012CA2809256A1 Compounds for treatment of cancer
03/01/2012CA2809228A1 Crosslinked hyaluronic acid composition and self-crosslinking hyaluronic acid particles
03/01/2012CA2809120A1 Crystal of tricyclic pyrazolopyrimidine derivative
03/01/2012CA2809086A1 Pure intermediate
03/01/2012CA2809071A1 Composition and method of manufacture
03/01/2012CA2809031A1 Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
03/01/2012CA2808889A1 Mir-33 inhibitors and uses thereof
03/01/2012CA2808841A1 Antimetastatic compounds
03/01/2012CA2808680A1 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
03/01/2012CA2808520A1 Methods for the treatment or prophylaxis of thrombosis or embolism
03/01/2012CA2808501A1 Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
03/01/2012CA2808495A1 Synbiotic product
03/01/2012CA2808359A1 Certain chemical entities, compositions, and methods
03/01/2012CA2808225A1 Compositions and methods for cardiac therapy
03/01/2012CA2807968A1 Salt compound
03/01/2012CA2807965A1 Methods for treating antipsychotic-induced weight gain
03/01/2012CA2807830A1 Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
03/01/2012CA2807738A1 Hydroxamate-based inhibitors of deacetylases
03/01/2012CA2807062A1 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
03/01/2012CA2807000A1 Proline sulfonamide derivatives as orexin receptor antagonists
03/01/2012CA2806900A1 Pyridyl-amine fused azadecalin modulators
03/01/2012CA2805932A1 Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012CA2804824A1 Substituted quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012CA2802870A1 Pesticidal compositions
03/01/2012CA2802721A1 Novel agonists of toll-like receptor 3 and methods of their use
02/2012
02/29/2012EP2423335A2 Chimeric immunomodulatory compounds and methods of using the same
02/29/2012EP2423328A2 Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
02/29/2012EP2423324A1 Probe set for identification of nucleotide mutation, and method for identification of nucleotide mutation
02/29/2012EP2423319A1 Novel compound amycolamicin, method for production thereof, and use thereof
02/29/2012EP2423310A1 Cancer antigen helper peptide
02/29/2012EP2423291A1 1-menthyl (3r)-3-hydroxybutanoate, process for producing same, and composition containing same for stimulating sense
02/29/2012EP2423290A1 Process for producing 1-menthyl (3s)-3-hydroxybutanoate and composition for stimulating sense
02/29/2012EP2423231A2 PRLR-specific antibody and uses thereof
02/29/2012EP2423215A1 Prodrugs based on gemcitabine structure as well as synthetic method and application thereof
02/29/2012EP2423213A1 Preparation and use of novel antibiotic, anticancer compounds and derivatives thereof
02/29/2012EP2423208A1 Pharmaceutically active compounds as Axl inhibitors
02/29/2012EP2423207A2 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
02/29/2012EP2423204A1 Thiazolidinone derivative
02/29/2012EP2423203A1 Crystal of benzoxazinone compound
1 ... 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 ... 7860